Suppr超能文献

一种在健康成年人中比较常规静脉血采样与两种微采样技术的瑞马唑仑口服混悬液的药代动力学研究。

A pharmacokinetic study of radiprodil oral suspension in healthy adults comparing conventional venous blood sampling with two microsampling techniques.

机构信息

UCB Biopharma SPRL Braine l'Alleud Belgium.

PRA Health Sciences - Early Development Services (PRA-EDS) Groningen The Netherlands.

出版信息

Pharmacol Res Perspect. 2019 Jan 28;7(1):e00459. doi: 10.1002/prp2.459. eCollection 2019 Feb.

Abstract

In this phase I, single-center, open-label study of ten heathy adults (18-45 years; NCT02647697), the PK, safety, and tolerability profile of radiprodil oral suspension in healthy adults were assessed, as well as two PK microsampling techniques. All participants received a single 30 mg radiprodil dose (12 mL oral suspension). Blood was collected at various time points using conventional venous sampling (intravenous catheter or venepuncture), and Mitra™ and Aqua-Cap™ Drummond microsampling (finger-prick and blood taken from venous blood sample tubes). Geometric mean radiprodil plasma concentrations from conventional venous samples were above the lower limit of quantification up to 48 hours after administration of a single oral dose of radiprodil. Geometric mean AUC and were 2042 h ng mL and 89.4 ng mL , respectively. Geometric mean was 15.8 hour; median was 4 hour (range: 3-6 hour). Radiprodil exposure variables for Aqua-Cap™ Drummond sampling were similar to the conventional venous-derived data. Conversely, radiprodil exposure variables were lower with Mitra™ sampling compared with conventional venous sampling. The geometric mean ratio (90% confidence interval) for of conventional venous versus Mitra™ and Aqua-Cap™ Drummond sampling (finger-prick blood) was 0.89 (0.85, 0.94) and 1.03 (0.97,1.08), respectively, and therefore within the conventional bioequivalence range (0.80-1.25). Radiprodil oral suspension had an acceptable safety, tolerability, and palatability profile. The PK profile of radiprodil oral suspension was established in healthy adults, and was comparable when analyzed using conventional versus microsampling techniques. These results will support future radiprodil paediatric studies.

摘要

在这项 I 期、单中心、开放标签的研究中,纳入了 10 名健康成年人(18-45 岁;NCT02647697),评估了健康成年人中单剂量雷迪普罗口服混悬液的药代动力学、安全性和耐受性特征,以及两种药代动力学微采样技术。所有参与者均接受了单次 30mg 雷迪普罗剂量(12mL 口服混悬液)。使用常规静脉采样(静脉内导管或静脉穿刺)和 Mitra™和 Aqua-Cap™ Drummond 微采样(指尖采血和从静脉血样管中采集血液)在不同时间点采集血液。从常规静脉样本中获得的雷迪普罗几何平均血浆浓度在单次口服雷迪普罗给药后 48 小时内均高于定量下限。AUC 和 的几何平均值分别为 2042h ng mL 和 89.4ng mL 。 的几何平均值为 15.8 小时;中位数为 4 小时(范围:3-6 小时)。Aqua-Cap™ Drummond 采样的雷迪普罗暴露变量与常规静脉衍生数据相似。相反,与常规静脉采样相比,Mitra™采样的雷迪普罗暴露变量较低。常规静脉与 Mitra™和 Aqua-Cap™ Drummond (指尖采血)采样的 的几何平均比值(90%置信区间)分别为 0.89(0.85,0.94)和 1.03(0.97,1.08),因此在常规生物等效性范围内(0.80-1.25)。雷迪普罗口服混悬液具有可接受的安全性、耐受性和口感。在健康成年人中建立了雷迪普罗口服混悬液的药代动力学特征,当使用常规采样技术与微采样技术进行分析时,其结果具有可比性。这些结果将支持未来的雷迪普罗儿科研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验